Tina Nguyen, Tanya Markary, Ni-Chun Tsai, Katrin Tiemann, Sally Mokhtari, Yazeed Samara, Hoda Pourhassan, Amanda Blackmon, Shukaib Arslan, Salman Otoukesh, Vaibhav Agarwal, Idoroenyi Amanam, Brian Ball, Paul Koller, Ahmed Aribi, Amandeep Salhotra, Karamjeet Sandhu, Vinod Pullarkat, Pamela Becker, Ibrahim Aldoss, Haris Ali, Forrest Stewart, Eileen Smith, Anthony Stein, Guido Marcucci, Stephen J Forman, Andrew Artz, Ryotaro Nakamura, Monzr M Al Malki
{"title":"Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment.","authors":"Tina Nguyen, Tanya Markary, Ni-Chun Tsai, Katrin Tiemann, Sally Mokhtari, Yazeed Samara, Hoda Pourhassan, Amanda Blackmon, Shukaib Arslan, Salman Otoukesh, Vaibhav Agarwal, Idoroenyi Amanam, Brian Ball, Paul Koller, Ahmed Aribi, Amandeep Salhotra, Karamjeet Sandhu, Vinod Pullarkat, Pamela Becker, Ibrahim Aldoss, Haris Ali, Forrest Stewart, Eileen Smith, Anthony Stein, Guido Marcucci, Stephen J Forman, Andrew Artz, Ryotaro Nakamura, Monzr M Al Malki","doi":"10.1016/j.jtct.2025.07.001","DOIUrl":null,"url":null,"abstract":"<p><p>Renal impairment is associated with poor outcomes following allogeneic hematopoietic cell transplantation (HCT). Although melphalan-based reduced-intensity conditioning (RIC) is demonstrated to be safe and feasible in older HCT patients, the impact of renal impairment on outcomes and toxicities following melphalan-based RIC is not well described. To evaluate how pretransplant renal function influences toxicity and survival after fludarabine/melphalan (FM) RIC and to compare measured 24-h urine creatinine clearance (UCrCl) with calculated creatinine-based renal function estimates as prognostic markers. Herein, we describe long-term outcomes of 561 HCT patients aged 55 to 74 years who received FM conditioning and tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis prior to matched donor HCT, between July 2009 and December 2019. Patients were divided based on pre-HCT UCrCl: creatinine clearance (CrCl) <90 mL/min (UCrCl 2 to 3, n = 184) and CrCl ≥90 mL/min (UCrCl 0 to 1, n = 377). CrCl for all patients was also calculated by the Cockcroft-Gault and the 2021 Chronic Kidney Disease Epidemiology Collaboration equations for comparison. UCrCl 2 to 3 correlated with higher 4-year non-relapse mortality (31% versus 19%, P < .01) and lower 4-year overall survival (55% versus 62%, P = .03) without differences in relapse rates. Neither CrCl calculation method correlated with any survival endpoint. UCrCl 2 to 3 was associated with higher severity and incidence of melphalan-related adverse events. Lower UCrCl was associated with less melphalan-induced severe GVHD- and gastrointestinal toxicity-free survival (MGTFS), a composite endpoint for severe melphalan-related morbidity and mortality at day +30 post-HCT and an early correlate of long-term survival outcomes (UCrCl 2 to 3: 18% versus UCrCl 0 to 1: 31%, P < .01). Patients with poor baseline UCrCl receiving melphalan-based RIC are at risk for significant conditioning-related toxicity and GVHD and, consequently, increased mortality. MGTFS quantified the early effect of FM RIC-related toxicities on post-HCT survival in this renally impaired HCT population.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2025.07.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Renal impairment is associated with poor outcomes following allogeneic hematopoietic cell transplantation (HCT). Although melphalan-based reduced-intensity conditioning (RIC) is demonstrated to be safe and feasible in older HCT patients, the impact of renal impairment on outcomes and toxicities following melphalan-based RIC is not well described. To evaluate how pretransplant renal function influences toxicity and survival after fludarabine/melphalan (FM) RIC and to compare measured 24-h urine creatinine clearance (UCrCl) with calculated creatinine-based renal function estimates as prognostic markers. Herein, we describe long-term outcomes of 561 HCT patients aged 55 to 74 years who received FM conditioning and tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis prior to matched donor HCT, between July 2009 and December 2019. Patients were divided based on pre-HCT UCrCl: creatinine clearance (CrCl) <90 mL/min (UCrCl 2 to 3, n = 184) and CrCl ≥90 mL/min (UCrCl 0 to 1, n = 377). CrCl for all patients was also calculated by the Cockcroft-Gault and the 2021 Chronic Kidney Disease Epidemiology Collaboration equations for comparison. UCrCl 2 to 3 correlated with higher 4-year non-relapse mortality (31% versus 19%, P < .01) and lower 4-year overall survival (55% versus 62%, P = .03) without differences in relapse rates. Neither CrCl calculation method correlated with any survival endpoint. UCrCl 2 to 3 was associated with higher severity and incidence of melphalan-related adverse events. Lower UCrCl was associated with less melphalan-induced severe GVHD- and gastrointestinal toxicity-free survival (MGTFS), a composite endpoint for severe melphalan-related morbidity and mortality at day +30 post-HCT and an early correlate of long-term survival outcomes (UCrCl 2 to 3: 18% versus UCrCl 0 to 1: 31%, P < .01). Patients with poor baseline UCrCl receiving melphalan-based RIC are at risk for significant conditioning-related toxicity and GVHD and, consequently, increased mortality. MGTFS quantified the early effect of FM RIC-related toxicities on post-HCT survival in this renally impaired HCT population.